Bionetide

2025 年，是 MECP2 基因相关疾病（尤其是雷特综合征）研究发生深刻变化的一年。 一方面，针对雷特综合征的权威诊疗指南正式发布，为疾病的规范化管理与临床决策奠定了坚实基础；另一方面，基因治疗领域完成了从早期探索迈向注册性临床试验的关键跨越，标志着该领域进入临床转化的实质阶段；突破背后，围绕高剂量治疗的安全性事件也促使行业重新审视风险与边界。与此同时，中国在源头创新方面实现了重要突破，多款国产基因治疗产品相继启动研究者发起的临床研究（IIT）。 本文将为您梳理这一年 MECP2 基因相关疾病药物研发领域的核心进展与趋势。一、 2025 年度“里程碑式突破”1. 【政策标准】国家卫健委发布《雷特综合征诊疗指南（2025版）》 • 核心发现：2025年7月，中国国家卫生健康委员会正式发布针对《第二批罕见病目录》中雷特综合征的官方诊疗指南。 • 意义：填补了中国在该领域国家级指导文件的空白。标志着中国雷特综合征的临床诊疗、分期评估及多学科管理迈入有据可依的规范化新阶段，对提升确诊率和患者生存质量具有基础性意义。2. 【临床验证】两大基因疗法（TSHA-102 & NGN-401）全面进入注册性试验阶段 • 核心发现： • TSHA-102：获 FDA “突破性疗法”认定，并就关键性试验设计达成一致。 • NGN-401：获 FDA 书面同意其 Embolden™ 注册性试验方案，并于 11 月完成首例患者给药。 • 共同趋势：两者均获得了监管机构的认可，采用单臂设计（不设安慰剂组，以患者自身基线为对照），并将“功能性技能获得” 确立为核心终点。 • 意义：标志着雷特综合征基因治疗正式从“早期安全性探索”迈入“确证性疗效”阶段，且监管机构（FDA）对神经发育类罕见病的审批标准展现出了极大的灵活性（认可自然病史对照，认可生活技能作为硬指标）。3. 【源头创新】中国自主研发基因/RNA 疗法初见疗效 • 核心发现： • GCB-002：由上海金珂博公司研发，在上海交通大学医学院附属新华医院（余永国教授团队） 完成国内首例雷特综合征基因治疗给药。 • Rett-001：由上海交通大学医学院松江研究院仇子龙团队研发，在广州医科大学附属妇女儿童医疗中心（周文浩教授团队） 完成首例给药，探索单次鞘内注射的安全性与疗效。 • HG204：辉大基因开发的 RNA 编辑疗法，去年在北京大学第一医院完成了全球首例 MECP2 重复综合征患儿给药，于今年报道观察到初步疗效。 • 意义：标志着中国在 MECP2 基因相关疾病领域从“跟随者”转向“并行者”。特别是 HG204 的临床应用，验证了 RNA 编辑技术在神经系统疾病中的可行性，为该技术未来拓展至雷特综合征治疗奠定了基础。二、 2025年度药物研究趋势分析1. 治疗策略：从“简单替代”走向“精准调控”与“RNA编辑”的分化 • 基因替代仍是雷特综合征（Rett）的主流：针对 MECP2 缺失的雷特综合征，目前的临床重点依然是基因替代疗法（NGN-401, TSHA-102，GCB-002，Rett-001）。 • RNA编辑技术崭露头角： • MECP2 重复综合征（MDS）：辉大基因的 HG204 正处于IIT和早期临床试验阶段，利用 Cas13 在 RNA 水平降低过量的 MECP2，展示了 RNA 编辑在神经系统罕见病中的应用潜力。 • 雷特综合征：针对 Rett 中特定点突变（如 R270X）的 RNA 编辑（A-to-I 编辑修复无义突变）目前主要处于临床前研究阶段（如 ShapeTX, ProQR 的研究），虽尚未进入人体试验，但因其不改动 DNA 的可逆性和安全性，被视为下一代极具潜力的治疗方向。2. 临床终点从“主观量表”转向“功能性里程碑” 以往临床试验多依赖 RSBQ 或 CGI-I 等主观评分量表，容易产生安慰剂效应且缺乏临床实感。 2025 年的显著趋势是，无论是 NGN-401 还是 TSHA-102，其注册性试验均将 “具体技能获得”（如：从无法独坐到能独坐，从无语言到有意义的短语）作为核心终点。这反映了药物研发更务实，更贴近患者“改变生活”的真实需求。3. 药物类型：小分子药物向“多靶点”迭代 虽然基因疗法占据 C 位，但小分子药物并未退场，而是向更安全、耐受性更好的方向迭代。 • Trofinetide（Daybue） 推出了粉剂（STIX）以改善服用体验，临床也在探索通过饮食管理（如添加米粉）来缓解腹泻副作用。 • 新一代小分子：针对线粒体功能的 Leriglitazone、针对神经保护的 NA-921、针对 NMDAR 的艾司氯胺酮等纷纷进入临床视野。这表明行业在追求“治本”的同时，也在积极寻找更安全、更经济的“治标”或“改善功能”的药物组合。三、总结与展望 2025年，雷特综合征基因疗法的临床验证取得了实质性进展，同时也确立了更为严格的安全红线。步入 2026 年，期待行业继续秉持严谨的科学态度，扎实推进临床试验，早日为患者带来安全有效的治疗方案。 免责声明：「守望雷特 Rett Watchers」微信公众号专注介绍雷特综合征及其相关疾病的研究进展。本文仅作信息交流之目的，非治疗方案推荐，如需获得治疗方案指导，请前往正规医院就诊。「守望雷特 Rett Watchers」微信公众号不对任何主体因使用本文内容而导致的任何损失承担责任。 版权说明：本文由「守望雷特 Rett Watchers」微信公众号根据公开资料整理编辑，如需转载请注明出处。 文章撰写：伊尔文章排版：伊尔

Biomed Industries, Inc. to Present Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS Conference, October 18-20, 2025 in Lisbon, Portugal. The Phase 2/3 results of NA-921 show strong potential as an effective, well-tolerated treatment with a favorable safety profile, promising better patient adherence and improved long-term outcomes” — Dr. Lloyd L. Tran, CEO of Biomed SAN JOSE, CA, UNITED STATES, October 6, 2025 / EINPresswire.com / -- - Biomed Industries, Inc . (Biomed) today announced that its Chief Executive Officer, Dr. Lloyd L. Tran, will present the topline results of Phase 2/3 clinical trials of NA-921, a novel investigational treatment for Rett syndrome at the European Academy of Paediatric Societies (EAPS), October 18-20, 2025 in Lisbon, Portugal. The presentation, titled “PHASE 2 CLINICAL TRIALS RESULTS OF NA-921 FOR THE TREATMENT OF RETT SYNDROME ", summarizes findings from a randomized, double-blind, placebo-controlled Phase 2/3 study conducted in girls and young women aged 5 to 20 years diagnosed with Rett syndrome (ClinicalTrials.gov Identifier: NCT06849973). KEY FINDINGS: The topline results from the study demonstrate compelling proof of safety and efficacy for NA-921, an orally administered small molecule. Biomed conducted a comparative analysis of adverse reactions observed in the clinical trials, showing a significantly improved safety and tolerability profile for NA-921. COMPARISON WITH CURRENT TREATMENTS: While FDA-approved treatments such as DAYBUE™ have shown clinical efficacy, they come with significant safety concerns, including high rates of severe diarrhea, vomiting, and weight loss (Treatment Management Guide for Healthcare Professionals by Acadia Pharmaceuticals, Inc. https://www.daybuehcp.com/treatment-management-guide.pdf ). A comparison of clinical trial data between NA-921 and DAYBUE revealed the following: • Lower incidences of common side effects: Diarrhea (14% for NA-921 vs. 82% for DAYBUE) and vomiting (8% for NA-921 vs. 29% for DAYBUE). • Improved treatment retention: Unlike the DAYBUE trial, where 35.7% of patients discontinued treatment due to adverse events, no patients withdrew from the NA-921 trial. The details of the findings will be presented at the EAPS Conference. These results underscore Biomed Industries’ commitment to developing safer, more effective therapies that can significantly improve patient outcomes. “Our latest clinical data reinforce NA-921’s potential to provide a more effective and well-tolerated treatment option,” said Dr. Lloyd L. Tran, CEO of Biomed Industries, Inc. “Unlike existing therapies, which are often associated with severe gastrointestinal side effects and high discontinuation rates, NA-921 has demonstrated a remarkably low incidence of adverse events. With a favorable safety profile, NA-921 represents a promising treatment that could enhance patient adherence and long-term outcomes.” Biomed Industries is advancing NA-921 into the next phase of clinical trials to further assess its efficacy and long-term safety. AN UNMET NEED IN RETT SYNDROME Rett syndrome is a rare and severe neuro-developmental disorder that primarily affects females and is often caused by mutations in the MECP2 gene on the X chromosome. Approximately 16,000 individuals in the United States and 100,000 worldwide are affected by the condition (Rett Syndrome Research Trust). There are currently no curative treatments for Rett syndrome. Management strategies focus on alleviating symptoms and improving quality of life. The disorder progresses through four stages, beginning with developmental delays and slowed growth between 6 and 18 months of age. As it advances, individuals experience motor impairments, loss of speech, seizures, breathing difficulties, and profound cognitive and physical disabilities, requiring lifelong care. ABOUT BIOMED INDUSTRIES, INC. Biomed Industries, Inc. is a pioneering biopharmaceutical company dedicated to developing and commercializing novel drug therapeutics to address unmet medical needs. The company's research team has developed a new platform of drugs targeting Alzheimer’s disease, ALS, Major Depressive Disorder (MDD), Diabetes, Obesity, Metabolic dysfunction-associated Steatohepatitis (MASH), and rare diseases, including Rett Syndrome and Fragile X. Michael Willis Biomed Industries, Inc. +1 800-824-5135 email us here Visit us on social media: LinkedIn X Biomed introduction video Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.